Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REJOICE-PanTumor01 of raludotatug deruxtecan in advanced or metastatic solid tumors
jRCT2031240486Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of raludotatug deruxtecan in Nonhematologic neoplasms, endometrial cancer (EC), ovarian cancer and 1 more, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Objective response rate, Disease control rate and 1 more. Started Jan 2025; status: active, not recruiting.
02
Drugs
raludotatug deruxtecan
03
Conditions
Nonhematologic neoplasmsendometrial cancer (EC)ovarian cancerclear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on jRCT2031240486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240486.